Previous Pause Next
Home >> News Center >>
Clinical Trials
Catabasis Pharmaceuticals Initiates Phase 1 Clinical Trial of Lead Compound CAT-1004 PDF Print E-mail
Wednesday, 05 October 2011 06:36

Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids to create therapeutics for the treatment of inflammatory and metabolic diseases, today announced the initiation of a Phase 1 clinical trial for its lead product candidate CAT-1004.

Lightlake Therapeutics Inc. to Conduct Phase II Testing of New Bulimia Nervosa Treatment at King’s College London PDF Print E-mail
Wednesday, 05 October 2011 06:33

Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company using its expertise of opioid antagonists to develop modern addiction treatments, announced today that it will conduct Phase II trials at King’s College London on an opioid antagonist-based nasal spray treatment for Bulimia Nervosa.

InSite Vision Announces Positive Phase 2 PK Results for BromSite™ (ISV-303) for the Reduction of Pain and Inflammation After Cataract Surgery PDF Print E-mail
Tuesday, 04 October 2011 18:15

InSite Vision Incorporated (OTCBB:INSV) today announced positive top-line results from a Phase 2 pharmacokinetic (PK) clinical study comparing the tissue penetration profile of InSite Vision’s BromSite (ISV-303) with ISTA Pharmaceuticals’ Bromday (bromfenac ophthalmic solution) 0.09%.

Penn-Developed Online Informed Consent Tool Could Boost Number Of Patients In Cancer Clinical Trials PDF Print E-mail
Tuesday, 04 October 2011 18:11

A new multimedia informed consent tool accessed via the Internet may make it easier for cancer patients to understand and feel comfortable enrolling in clinical trials, according a study conducted by researchers in the Perelman School of Medicine at the University of Pennsylvania that will be presented at the American Society for Radiation Oncology's (ASTRO) 53rd Annual Meeting.

Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation PDF Print E-mail
Monday, 03 October 2011 05:58

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation (OIC).

AMRI Presents Final Phase I Clinical Studies Results of Obesity Compound at the 29th Annual Scientific Meeting of the Obesity Society PDF Print E-mail
Monday, 03 October 2011 05:52

AMRI (NASDAQ: AMRI) announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla. Nicholas Moore, Ph.D., director of development and pharmacology at AMRI, reported results from a second Phase I study showing cerebrospinal fluid (CSF) drug levels were achieved with a single 400 mg oral dose of ALB-127158(a).

Telik Announces Publication In The Journal Cancer Of A Phase 2 Randomized Multicenter Study Of Two Extended Dosing Schedules Of Oral Ezatiostat In Low To Intermediate-1 Risk Myelodysplastic Syndrome PDF Print E-mail
Saturday, 01 October 2011 04:48
Telik, Inc. today announced the publication in the journal Cancer of A Phase 2 Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS), Raza, A., et al., Cancer, doi: 10.1002/cncr.26469, September 1, 2011.
Defense Witness In Second Hepatitis C Trial In Nevada, Dr. Arthur Reingold, Testimony on Plausible Cause for Contamination Impeached PDF Print E-mail
Saturday, 01 October 2011 04:43

Dr. Arthur Reingold, witness for the defense in the second hepatitis C trial in Nevada, was called to the stand today offering expert testimony as an epidemiologist.

Topline Results: A Randomized Phase 2 Study of Selumetinib in Patients with KRAS-Mutant Non-Small Cell Lung Cancer PDF Print E-mail
Friday, 30 September 2011 20:51

Array BioPharma Inc. (NASDAQ: ARRY) today announced results from a randomized Phase 2 placebo-controlled study conducted by AstraZeneca comparing the efficacy of selumetinib (AZD6244/ARRY-886) in combination with docetaxel with docetaxel alone in the second-line treatment of 87 patients prospectively selected with KRAS-mutant, locally advanced or metastatic non-small cell lung cancer.

Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit PDF Print E-mail
Friday, 30 September 2011 20:46
Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit (ALS Summit) on Saturday, October 1, 2011.
Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer PDF Print E-mail
Wednesday, 05 October 2011 06:35
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today announced that a manuscript entitled, "Randomized Placebo-Controlled Phase 2 Trial of Perifosine Plus Capecitabine as Second- or Third-Line Therapy in Patients with Metastatic Colorectal Cancer " reporting Phase 2 activity of perifosine (KRX-0401) in the treatment of patients with refractory, advanced colorectal cancer (mCRC), was selected for publication in the October 3, 2011 online edition of the Journal of Clinical Oncology (JCO).
CytRx’s ENABLE Phase 2 Trial Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia to be Presented at the Prestigious 53rd Annual ASH Meeting PDF Print E-mail
Tuesday, 04 October 2011 18:18

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that an abstract with results from the Company’s ENABLE Phase 2 proof-of-concept clinical trial with its Bcr-Abl, Lyn and Fyn kinase inhibitor bafetinib for the treatment of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments will be presented in a poster session at the 2011 American Society of Hematology (ASH®) Annual Meeting on Sunday, December 11, 2011 at 6:00 p.m. Pacific time at the San Diego Convention Center, Hall GH.

Initial Data from Bio-Path Holdings’ Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting PDF Print E-mail
Tuesday, 04 October 2011 18:14

Bio-Path Holdings, Inc. (OTC BB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that an abstract entitled, “Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)” has been accepted for a poster presentation at the 53rd Annual Meeting of the American Society of Hematology (ASH) to be held December 10 to 13, 2011 in San Diego, California.

Auxilium Pharmaceuticals, Inc. Announces First Patient Enrolled in XIAFLEX® Phase IIIb Dupuytren's Contracture Multicord Study PDF Print E-mail
Monday, 03 October 2011 05:59
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the first patients have been dosed in the Company's phase IIIb trial of XIAFLEX® for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. 
Santaris Pharma A/S to Report New Clinical Data From Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting PDF Print E-mail
Monday, 03 October 2011 05:55
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.
GeoVax Phase 2a Clinical Trial Completes Enrollment PDF Print E-mail
Monday, 03 October 2011 05:50
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.
Children's Oncology Group And Apeiron To Jointly Conduct Phase II Study In Neuroblastoma With Hu14.18-IL2 (APN301) PDF Print E-mail
Saturday, 01 October 2011 04:46

Children's Oncology Group (COG) and APEIRON Biologics AG (Apeiron) announced today that they will jointly investigate Apeiron's APN301 in a clinical phase II study in pediatric neuroblastoma patients.

Durata Therapeutics Initiates Enrollment in DISCOVER-2, Second Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections PDF Print E-mail
Friday, 30 September 2011 20:53

Durata Therapeutics today announced the Company has initiated enrollment in a second global, pivotal, Phase 3 study (DISCOVER-2) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI).

Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis PDF Print E-mail
Friday, 30 September 2011 20:50

Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Trial of SB-509 in Diabetic Neuropathy PDF Print E-mail
Friday, 30 September 2011 20:45
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial (SB-509-901) from its ZFP Therapeutic® program to develop SB-509 as a treatment for diabetic neuropathy.  
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 122